Literature DB >> 11512088

Human herpesvirus 6.

M T Caserta1, D J Mock, S Dewhurst.   

Abstract

The development of techniques for the culture of lymphoid cells and the isolation of viruses that infect these cells led to the discovery of human herpesvirus (HHV) 6 in 1986. At the time, HHV-6 was the first new human herpesvirus to be discovered in roughly a quarter of a century, and its isolation marked the beginning of an era of discovery in herpesvirology, with the identification of HHV-7 and HHV-8 (Kaposi's sarcoma-associated herpesvirus) during the following decade. Like most human herpesviruses, HHV-6 is ubiquitous and capable of establishing a lifelong, latent infection of its host. HHV-6 is particularly efficient at infecting infants and young children, and primary infection with the virus is associated with roseola infantum (exanthem subitum) and, most commonly, an undifferentiated febrile illness. Viral reactivation in the immunocompromised host has been linked to a variety of diseases, including encephalitis, and HHV-6 has been tentatively associated with multiple sclerosis. This article discusses the major properties of HHV-6, its association with human disease, and the pathobiological significance of viral reactivation.

Entities:  

Mesh:

Year:  2001        PMID: 11512088     DOI: 10.1086/322691

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  33 in total

1.  Recognition of a novel stage of betaherpesvirus latency in human herpesvirus 6.

Authors:  Kazuhiro Kondo; Junji Sashihara; Kazuya Shimada; Masaya Takemoto; Kiyoko Amo; Hiromi Miyagawa; Koichi Yamanishi
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  MR imaging of human herpesvirus-6 encephalopathy after hematopoietic stem cell transplantation in adults.

Authors:  T Noguchi; F Mihara; T Yoshiura; O Togao; K Atsumi; T Matsuura; T Kuroiwa; H Honda
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

3.  Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis.

Authors:  Elisabetta Caselli; Michela Boni; Arianna Bracci; Antonella Rotola; Claudio Cermelli; Massimiliano Castellazzi; Dario Di Luca; Enzo Cassai
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

4.  Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review.

Authors:  Elda Righi; Alessia Carnelutti; Daniele Muser; Francesco Zaja; Elisa Lucchini; Federico Pea; Fernando Di Gregorio; Abass Alavi; Matteo Bassetti
Journal:  J Neurovirol       Date:  2017-08-18       Impact factor: 2.643

5.  Herpesvirus infections of the central nervous system in immunocompromised patients.

Authors:  Uta Meyding-Lamadé; Cornelia Strank
Journal:  Ther Adv Neurol Disord       Date:  2012-09       Impact factor: 6.570

6.  Detection of a gene cluster that is dispensable for human herpesvirus 6 replication and latency.

Authors:  Kazuhiro Kondo; Hideo Nozaki; Kazuya Shimada; Koichi Yamanishi
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 7.  Advances in pediatric neurovirology.

Authors:  John R Crawford
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

Review 8.  Human herpes virus 6B: a possible role in epilepsy?

Authors:  William H Theodore; Leon Epstein; William D Gaillard; Shlomo Shinnar; Mark S Wainwright; Steven Jacobson
Journal:  Epilepsia       Date:  2008-07-08       Impact factor: 5.864

9.  Detection of human herpesvirus-6 in mesial temporal lobe epilepsy surgical brain resections.

Authors:  D Donati; N Akhyani; A Fogdell-Hahn; C Cermelli; R Cassiani-Ingoni; A Vortmeyer; J D Heiss; P Cogen; W D Gaillard; S Sato; W H Theodore; S Jacobson
Journal:  Neurology       Date:  2003-11-25       Impact factor: 9.910

10.  Prevalence of human herpesvirus 6 antibodies and DNA in allogeneic stem cell transplant patients: two-year single centre experience.

Authors:  Tomasz Dzieciatkowski; Maciej Przybylski; Tigran Torosian; Agnieszka Tomaszewska; Mirosław Luczak
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.